Introduction
Cystic fibrosis (CF), a fatal genetic disease afflicting mainly people of Caucasian origin, is caused by malfunction of Cystic Fibrosis Transmembrane conductance Regulator (CFTR), a chloride ion channel involved in transepithelial salt and water movement [1, 2] . While pathogenic mutations in CFTR could result in a variety of biochemical/ biophysical defects to perturb the secretory or absorptive function of epithelial cells [3, 4] , many of these diseaseassociated mutations, including the most prevalent one DF508-CFTR, cause abnormal gating (i.e., a reduced open probability, P o ). Thus, searching for reagents (CFTR potentiators) to restore the channel function of CFTR has been of great interest as it may lead to new CF treatment options for patients carrying such mutations.
Just like other members of the ABC (ATP-Binding Cassette) Transporter Superfamily, the CFTR protein is made of five distinctive domains, namely two transmembrane domains (TMDs), two nucleotide-binding domains (NBDs) and a regulatory (R) domain. It is well established that CFTR's R domain needs to be phosphorylated by protein kinase A (PKA) before the channel can be gated by ATP [5] . While the molecular mechanism for ATPdependent gating remains to be elucidated [6, 7] , it is generally accepted that gate opening is coupled to ATP binding-induced dimerization of CFTR's two NBDs in a head-to-tail configuration and gate closure is promoted by ATP hydrolysis at the catalysis-competent site (or site 2, composed of the head subdomain of NBD2 and the tail subdomain of NBD1) [8] . Although the detailed mechanism by which CFTR's NBDs are coupled to the gate in the TMDs continues to be debated [9] . For the purpose of discussion, in the current article we choose to use a model that conveniently explains mutation-induced gating defects as well as the action of CFTR potentiators (Figure 1 ). For example, the third most common diseaseassociated mutation G551D, also the first mutation subjected to targeted therapy (see below), has been shown to exhibit an extremely low P o (less than 1% of the P o of wildtype channels) likely due to a defect in ATP-induced NBD dimerization [10] [11] [12] . Thus, the rightmost horizontal transitions in Figure 1 are abolished by the G551D mutation. What is left for G551D-CFTR is ATP-independent spontaneous openings (see details in Ref. [13] ).
In this review, we will briefly review the history of studies on reagents that work as CFTR potentiators, discuss possible mechanisms of action for different agents, and elaborate ongoing challenges that need to be overcome to realize personalized medicine for cystic fibrosis.
higher affinity and efficacy in catalyzing NBD dimerization. Targeting CFTR's two ATP-binding sites indeed works! For example, addition of a small functional group to the N 6 position of the adenine ring has been demonstrated to significantly increase the P o of CFTR. Among the three ATP analogs studied by Zhou et al. [14] , N 6 -(2-phenylethyl)-ATP (P-ATP) is the one with the highest apparent affinity and efficacy. Indeed, P-ATP has been shown to increase the P o of G551D-CFTR (Figure 2 ) and DF508-CFTR by 7-fold and 5-fold respectively [15] . The main effect of P-ATP on G551D-CFTR is through an unexpected action on the catalysis-incompetent site (or site 1 composed of the head subdomain of NBD1 and the tail subdomain of NBD2). A different ATP analog 2 0 -deoxy-ATP (2 0 -dATP) also enhances gating of wild-type (WT) [12, 16] and G551D-CFTR [12] . Remarkably, N 6 -(2-phenylethyl)-2 0 -deoxy-ATP (P-dATP), a structural combination of P-ATP and dATP, increases the P o of G551D-CFTR by 36-fold as if these two chemical modifications in ATP act synergistically in potentiating G551D-CFTR gating [15] . Of note, accomplishing this level of opening probability for G551D-CFTR in vivo is expected to provide a functional cure for patients carrying such mutation. Although P-dATP completely rectifies the gating defect in DF508-CFTR [15] , its clinical utility is limited as ATP analogs are unlikely to become therapeutically useful due to bioavailability issues as well as potential non-specific interaction with countless ATP binding proteins involved in different physiological functions. Nonetheless, these studies using ATP analogs do provide proof-of-concept evidence for the feasibility of correcting gating defects for at least some of the most common pathogenic mutations.
The desire to find small-molecule CFTR-specific potentiators presents itself as a long list of chemicals that improve CFTR gating reported even a decade before the dawn of success in developing CFTR-targeted drugs [17] . As the cAMP-PKA signaling pathway constitutes the physiologically key step for CFTR activation, the first compound tested was IBMX (3-isobutyl-1-methylxanthine). Drumm et al. [18] proposed that IBMX, by inhibiting phosphodiesterase, increases intracellular cAMP and consequently PKA activity so that DF508-CFTR can be activated to a higher level. Then, Illek et al. [19, 20] demonstrated that genistein, a tyrosine kinase inhibitor found in many foods, can activate CFTR in intact cells through a mechanism indistinguishable from that of forskolin, an adenylyl cyclase activator. Three later studies however independently demonstrated that the CFTR protein itself is the target for genistein, establishing for the first time that CFTR itself can serve as a target for small-molecule CFTR potentiators [21] [22] [23] . Besides genistein, other flavonoid molecules have also been shown to enhance CFTR function both in vitro and in vivo [24] .
Another natural compound curcumin has also drawn significant interests as a potential therapeutic agent for CF. Curcumin was first reported as an effective CFTR corrector; it improves maturation of DF508-CFTR [25] (but cf. [26, 27] ). Similar to genistein, however, curcumin increases the P o of WT-CFTR by extending the opening burst duration and decreasing the interbust duration [28] . Moreover, curcumin potentiates DF508-CFTR to a similar extent as that of genistein [28] . Also like genistein [29] , curcumin works as a CFTR potentiator for G551D-CFTR [30] . Furthermore, the observation that curcumin enhances the activity of DNBD2-CFTR, a mutant with the entire NBD2 deleted, indicates that curcumin acts A gating scheme for WT-CFTR. An energetic coupling model modified from Ref. [7] . The top four states represent the closed states, whereas the lower four states are open channel conformations. This scheme illustrates the relationship between opening/closing of the gate in the TMDs (four vertical transitions), ATP binding/unbinding (two equal length horizontal transitions in the middle), NBD dimerization/ dissociation (the leftmost and rightmost horizontal transitions and AD means after dimerization with NBDs occupied by ATP), and ATP hydrolysis and dissociation of hydrolytic products (depicted as an unidirectional arrow). The yellow trapezoids represent CFTR's two TMDs, which craft a gated pore. The red and blue semicircles depict CFTR's NBD1 and NBD2 respectively. They jointly form the catalysisincompetent site 1 (lower binding pocket), and catalysis-competent site 2 (upper binding pocket). The different lengths of the arrows marking the transitions represent relatively different rate constants. The red arrows mark the two defective transitions in G551D, and blue arrows represent those affected by VX-770. Of note, even for the closed states, TMD conformations will change along with NBD dimerization. We propose that the recently solved closed channel structure with dimerized NBDs [57 through a mechanism that does not require ATP binding nor NBD dimerization [30] .
Evidence regarding the additive effect of genistein and curcumin for gating potentiation has been controversial. Berger et al. showed that in excised inside-out membrane patches, genistein inhibits curcumin-stimulated WT-CFTR current in a dose dependent manner [28] whereas a later study by Yu et al. reported the opposite result [31] . In both whole-cell and cell-attached patches containing G551D-CFTR, genistein and curcumin demonstrated an additive effect with a maximum 40-fold increase of CFTR currents under saturating concentrations [31, 32] . This apparent controversy might be due to different experimental conditions and/or contributions of intracellular factors.
VX-770 (Ivacaftor): a milestone in personalized medicine for CF In 2009, by using high throughput drug screening, Vertex Pharmaceuticals identified a compound, VX-770, that potently increases the activity of DF508-CFTR and G551D-CFTR in excised 'cell-free' membrane patches (Figure 3) , and significantly augments Cl À secretion in cultured CF bronchial epithelia isolated from patients carrying these mutations [33] . In subsequent phase II and phase III clinical trials [34, 35] , VX-770 effectively improved predicted FEV 1 (Forced Expiratory Volume in One second), decreased sweat chloride concentration and reduced the frequency of pulmonary exacerbations, all indicative of a beneficial clinical outcome. While the original clinical trials involved only patients carrying the G551D mutation, VX-770 (Ivacaftor or Kalydeco) was eventually approved for a variety of mutations that cause gating dysfunction [36] [37] [38] . The approval of VX-770 by the FDA in 2012 ushered in a new era of precision medicine that targets directly the underlying cause of CF.
The invention of Ivacaftor was no doubt one of the most important breakthroughs in the search for an ultimate cure of CF. However, very little was known about its mechanism of action at the time of its launch. It was reported [33, 39, 40] that VX-770 increases the P o of WT-CFTR by boosting its opening burst duration, which was thought to be dependent on the rate of ATP hydrolysis in CFTR's site 2 [6,41]. However, it is unlikely that VX-770 acts through delaying ATP hydrolysis because it is effective in hydrolysis-deficient mutants such as G551D [33, 39, 40] and E1371S [40] , as well as in WT-CFTR in the complete absence of ATP [39, 40] .
Although more studies are needed to eventually illuminate how VX-770 works at a molecular level, the gating model that features energetic coupling between NBD dimerization and gate opening/closing in the TMDs depicted in Figure 1 suffices to explain nearly all the experimental data with VX-770. We proposed that in the continuous presence of ATP, VX-770, by binding to WT-CFTR's TMDs, shifts the gating transitions towards the open state in the three vertical steps in Figure 1 (C 2 AD $ O 1 , C 2 ATP $ O 2 ATP, C 2 $ C 2 ) [40] . Thus, regardless of whether the ATP-induced NBD dimerization is intact as in the case of WT channels, or defective as in G551D-CFTR, whether ATP is hydrolyzed or not (for E1371S), and even whether the channel possesses two NBDs or not (in DNBD2-CFTR), VX-770 will improve gating function [13, 39, 40, 42] .
The basic research conducted in vitro provides the mechanistic basis for the near omnipotence of VX-770 in promoting the gating function of CFTR mutants. However, reagents other than VX-770 will be needed to rectify biochemical defects that are insensitive to VX-770. Furthermore, for reasons described below, there is an urgent need to develop new CFTR potentiators that may complement or supplant VX-770. To these ends, several recent biotechnological innovations provide tools and platforms for drug testing tailored to a specific genetic background often to the level of an individual patient. For example, rectal organoids derived from tissues collected in CF patients offer a highly precise and sensitive approach to test CFTR function and its pharmacological response based on an individual's genetic background [43] . Furthermore, the cutting-edge CRISPR technique has been successfully employed to create DF508 genotype in specific cell lines [44] . These new inventions add
Figure 3
Effects of VX-770 on G551D-CFTR. Representative single-channel current traces of G551D-CFTR in the absence or presence of 200 nM of VX-770. Of note, in the presence of VX-770, there are more opening events in the same duration of recording (i.e. an increased opening rate), and the opening bursts are significantly prolonged compared to those in the absence of VX-770 (i.e. a decrease of the closing rate). These two kinetic effects of VX-770 seen in all CFTR constructs we have tested [13, 40, 42, 54 ,55
,59], increase the P o of G551D-CFTR by $10-fold so that the presence of the second channel is revealed, highlighting the technical difficulty in estimating the number of function channels in a patch-clamp experiment for mutants such as G551D with an extremely low P o (see Ref.
[10] for details).
powerful arsenals to the already rich resources for the development of novel therapy in CF.
Ongoing challenges and future perspectives VX-770 is no doubt a remarkable CFTR potentiator. However, for the most prevalent mutant DF508-CFTR, clinical trials with Ivacaftor alone failed to attain satisfying outcomes [45] probably due to multiple defects associated with the DF508 mutation. Interestingly, even with a combination regiment of VX-770 and VX-809 (aka Lumacaftor, a CFTR corrector [46] ), only moderate improvement was observed in clinical trials [47, 48] . Two recent papers present in vitro experimental data supporting the notion that a prolonged exposure of DF508-CFTR channels to VX-770 negatively impacts the effect of a CFTR corrector, VX-809, on CFTR trafficking and stability [49, 50] . Therefore, finding second-generation CFTR potentiators without this undesirable drug-drug interaction is an imminent task.
It should be noted that the negative impact of VX-770 on VX-809 observed in DF508-CFTR could be mutation specific. It is possible that this combination regiment can benefit patients carrying mutations other than DF508 since these two drugs act on two completely different steps for CFTR function. Lately, it was also shown that chronic co-treatment with Lumacaftor plus Ivacaftor restores stability of a small sub-population of DF508-CFTR Cl À channels with a majority of the mutants remaining destabilized [51 ] . A recent study showed that VX-770 acts additively with VX-809 to restore CFTR function in chronically treated R117H/ DF508 cells [52] . Surprisingly however, increased chloride conductance was not seen in W1282X cells despite the presence of adequate transcript levels when treated with both VX-770 and VX-809 [53] . As the combination of VX-770 and VX-809 (i.e. Orkambi) is now used clinically for treating patients carrying the DF508 mutation, it seems fitting to rigorously examine its effects on other CF mutations to potentially extend its application.
As described above, studies of CFTR gating modulation by ATP analogs and small-molecule experimental reagents have established pharmacological synergism in promoting CFTR gating for WT as well as mutant CFTR. One potentially fruitful approach is to identify chemicals that work synergistically with VX-770. Recent reports indeed verified this possibility at least for G551D and R117H [54 ,55 ] . These studies also provide evidence for multiple drug binding sites that may accommodate reagents with vastly different structures. The notion that these binding sites reside in different domains of CFTR also raises the possibility of structure-based drug design especially in light of the latest breakthrough in solving the first atomic structure of the whole CFTR protein [56 ] .
Conclusions
Over the past two decades, significant accomplishments have been made in CFTR pharmacology. The success in developing VX-770 (Ivacaftor) is an important milestone in our unwavering commitment to bringing personalized medicine to fruition for patients with CF. It also serves as a template for designing next-generation targeted therapy for CF. Nonetheless, continuous efforts from different fields and different scientific disciplines are needed in our pursuit of an ultimate cure for all CF patients. To our delight, recent advancements in all aspects of CF research have laid a solid foundation for an optimistic outlook that tailored therapy for each CF patient is within our reach.
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